top of page

Portfolio Companies

Facts & Figures

2

Initial Portfolio Companies

5

Major Unmet Need Indications Being Studied

5

Molecules In Development

Potential Revenue Generation

~$5BN

Companies

Skiaphos
Hematology

Therapeutic Area | Hematology


Lead Indication    | AML

Pre-Clin
IND
Phase I
Phase II
Phase III
Lead asset is an oral dual target ENL-AF9(MLLT1/3) & FLT3 Inhibitor with cellular activity across multiple AML genotypes and the ability to combine with standard-of-care agents

Aviator
Biosciences

Aviator_Biosciences_card.png

Therapeutic Area | Cardiometabolic


Lead Indications    | MASH
 

                              | Cardiomyopathy

Pre-Clin
IND
Phase I
Phase II
Phase III
Lead assets AVB-101 (Gal3) and AVB-102 (LOXL2) are oral, Phase 2-ready antifibrotics with human proof-of-biology and a derisked safety profile across >200 patients dosed
bottom of page